Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BPMUF NASDAQ:CRNX NASDAQ:HCM NASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMUFBasilea Pharmaceutica$61.34$55.67$47.50▼$61.34$807.83M0.290 shsN/ACRNXCrinetics Pharmaceuticals$30.41-1.8%$30.93$24.10▼$62.53$2.90B0.25806,128 shs525,062 shsHCMHUTCHMED$17.78+1.2%$15.50$11.51▼$21.50$3.06B0.5255,466 shs27,864 shsIMVTImmunovant$18.32-0.4%$16.18$12.72▼$34.47$3.15B0.631.13 million shs1.21 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMUFBasilea Pharmaceutica0.00%0.00%+6.31%+29.14%+30.51%CRNXCrinetics Pharmaceuticals+1.67%-2.88%+3.58%-7.22%-43.50%HCMHUTCHMED-0.62%+2.57%+15.52%+11.63%-7.04%IMVTImmunovant+2.51%+3.26%+18.88%+22.03%-34.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/AN/AN/AN/ACRNXCrinetics Pharmaceuticals3.7011 of 5 stars3.40.00.03.73.62.50.0HCMHUTCHMED2.8261 of 5 stars3.23.00.00.02.70.01.9IMVTImmunovant1.1098 of 5 stars3.40.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMUFBasilea Pharmaceutica 4.00Strong BuyN/AN/ACRNXCrinetics Pharmaceuticals 2.80Moderate Buy$69.50128.54% UpsideHCMHUTCHMED 2.33Hold$23.5032.17% UpsideIMVTImmunovant 2.82Moderate Buy$36.3098.14% UpsideCurrent Analyst Ratings BreakdownLatest BPMUF, IMVT, CRNX, and HCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025HCMHUTCHMEDBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $28.007/10/2025CRNXCrinetics PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$36.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.006/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.005/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMUFBasilea Pharmaceutica$236.92M3.41$6.85 per share8.96$6.99 per share8.78CRNXCrinetics Pharmaceuticals$1.04M2,737.78N/AN/A$14.29 per share2.13HCMHUTCHMED$630.20M4.92$0.29 per share61.17$4.43 per share4.01IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMUFBasilea Pharmaceutica$88.14MN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/7/2025 (Estimated)HCMHUTCHMED$37.73MN/A0.0012.18N/AN/AN/AN/A8/7/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)Latest BPMUF, IMVT, CRNX, and HCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13N/AN/AN/A$0.52 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMUFBasilea PharmaceuticaN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMUFBasilea Pharmaceutica1.184.854.16CRNXCrinetics PharmaceuticalsN/A22.5322.53HCMHUTCHMED0.082.832.70IMVTImmunovantN/A11.1611.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMUFBasilea PharmaceuticaN/ACRNXCrinetics Pharmaceuticals98.51%HCMHUTCHMED8.82%IMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipBPMUFBasilea PharmaceuticaN/ACRNXCrinetics Pharmaceuticals4.60%HCMHUTCHMED3.60%IMVTImmunovant1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMUFBasilea Pharmaceutica14713.17 millionN/ANot OptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableHCMHUTCHMED1,811174.42 million168.14 millionNot OptionableIMVTImmunovant120171.07 million167.99 millionOptionableBPMUF, IMVT, CRNX, and HCM HeadlinesRecent News About These CompaniesAll You Need to Know About Immunovant (IMVT) Rating Upgrade to BuyJuly 16, 2025 | zacks.comWall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?July 16, 2025 | zacks.comEmerald Advisers LLC Trims Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)July 14, 2025 | marketbeat.comImmunovant (IMVT) chief technology officer Stout sells $26k in stockJuly 13, 2025 | investing.comPrincipal Financial Group Inc. Sells 31,255 Shares of Immunovant, Inc. (NASDAQ:IMVT)July 13, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Insider Sells $19,998.40 in StockJuly 12, 2025 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) Insider Michael Geffner Sells 1,160 SharesJuly 11, 2025 | marketbeat.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CTO Sells 1,519 Shares of StockJuly 11, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Coverage Initiated by Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 7, 2025 | marketbeat.comLifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PTJuly 6, 2025 | msn.comImmunovant, Inc. (IMVT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comImmunovant (NASDAQ:IMVT) Stock Updated Nasdaq CompositeJune 23, 2025 | kalkinemedia.comKTracking Baker Brothers Portfolio - Q1 2025 UpdateJune 17, 2025 | seekingalpha.comImmunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)June 13, 2025 | seekingalpha.comImmunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?June 2, 2025 | zacks.comIMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in FocusMay 30, 2025 | zacks.comImmunovant, Inc. Reports Strategic Progress and Financial ResultsMay 29, 2025 | tipranks.comImmunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The FenceMay 29, 2025 | msn.comImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025May 29, 2025 | globenewswire.comH.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) StockMay 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPMUF, IMVT, CRNX, and HCM Company DescriptionsBasilea Pharmaceutica OTCMKTS:BPMUF$61.34 0.00 (0.00%) As of 07/23/2025Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.Crinetics Pharmaceuticals NASDAQ:CRNX$30.41 -0.57 (-1.84%) Closing price 04:00 PM EasternExtended Trading$30.30 -0.11 (-0.36%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.HUTCHMED NASDAQ:HCM$17.78 +0.21 (+1.20%) Closing price 04:00 PM EasternExtended Trading$17.81 +0.03 (+0.17%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$18.32 -0.07 (-0.38%) Closing price 04:00 PM EasternExtended Trading$18.24 -0.08 (-0.44%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
